Antifibrinolytic compounds

1. A compound of formula (I), or a pharmaceutically or veterinary acceptable salt thereof, or any stereoisomer either of the compound of formula (I) or of its pharmaceutically or veterinary acceptable salt

wherein A and B form a spirocyclic ring system selected from the group consisting of:

C is phenyl;

R 1 -R 3 are independently selected from H, halogen, —NO 2 , —CN, R a , —OR a′ , —OC(Y)R a′ , —OC(Y)OR a′ , —OC(Y)NR b R a′ , —OSO 2 OR a′ , —NR b R a′ , —NR b C(Y)R a′ , —NR b C(Y)OR a′ , —NR b C(Y)NR b R a′ , —NR b S(O) 2 R a′ , —NR b SO 2 NR b R a′ , —SR a′ , —S(O)R a′ , —S(O)OR a′ , —SO 2 R a′ , —SO 2 (OR a′ ), —SO 2 NR b R a′ , —SC(Y)NR b R a′ , —C(Y)R a′ , —C(Y)OR a′ , —C(Y)NR b R a′ , —C(Y)NR b OR a′ , and —C(O)NR b SO 2 R a′ ;

R 4 —R 5 are independently selected from halogen, —NO 2 , —CN, R c , —OR c , —NR d R c , —NR d C(Y)R c , —NR d C(Y)OR c , —NR d C(Y)NR d R c , —NR d S(O) 2 R c , —NR d SO 2 NR d R c , —SR c , —S(O)R c , —S(O)OR c , —SO 2 R c , —SO 2 R(OR c ), —SO 2 NR d R c , —SC(Y)NR d R c , —C(Y)R c , —C(Y)OR c , —C(Y)NR d R c , —C(Y)NR d OR c , and —C(O)NR d SO 2 R c ;

R a is a saturated or unsaturated (C 1 -C 12 )alkyl optionally substituted with one or more substituents R e and/or one Cy 1 ; or alternatively R a is Cy 2 ;

wherein Cy 1 and Cy 2 are independently optionally substituted with one or more substituents selected from R e and saturated or unsaturated (C 1 -C 6 ) alkyl optionally substituted with one or more substituents R e ;

each R a′ and R b are independently H or R a ;

R c and each R d are independently selected from H, Cy 4 , and saturated or unsaturated (C 1 -C 6 )alkyl optionally substituted with one or more substituents R h and/or one Cy 5 ;

wherein Cy 5 is optionally substituted with one or more substituents independently selected from R h and saturated or unsaturated (C 1 -C 6 )alkyl optionally substituted with one or more substituents R h ; and

wherein Cy 5 is optionally substituted with one or more substituents independently selected from R h and saturated or unsaturated (C 1 -C 6 ) alkyl optionally substituted with one or more substituents R h ;

each R e is independently selected from halogen, —NO 2 , —CN, —OR f , —OC(Y)R f , —OC(Y)OR f , —OC(Y)NR g R f , —NR g R f , —NR g C(Y)R f , —NR g C(Y)OR f , —NR g C(Y)NR g R f , —NR g S(O) 2 R f , —NR g SO 2 NR g R f , —SR f , —S(O)R f , —S(O)OR f , —SO 2 R f , —SO 2 (OR f ), —SO 2 NR g R f , —SC(Y)NR g R f , —C(Y)R f , —C(Y)OR f , —C(Y)NR g R f , —C(Y)NR g OR f and —C(O)NR g SO 2 R f ;

R f and each R g are independently selected from H, Cy 6 , and saturated or unsaturated (C 1 -C 6 )alkyl optionally substituted with one or more substituents R h and/or one Cy 7 ;

wherein Cy 6

any Cy 7 are optionally substituted with one or more substituents independently selected from R h and (C 1 -C 4 )alkyl optionally substituted with one or more substituents R h ;

each R h is independently selected from halogen, —NO 2 , —CN, —OR i , —OC(O)R i , —OC(O)OR i , —OC(O)NR i R i , —NR i C(O)R i , —NR i C(O)OR i , —NR i C(O)NR i R i , —NR i S(O) 2 R i , —NR i SO 2 NR i R i , —SR i , —S(O)R i , —SO 2 R i , —SO 2 (OR i ), —SO 2 NR i R i , —C(O)R i , —C(O)OR i , —C(O)NR i R i , and —C(O)NR i OR i ;

each R i is independently H or —(C 1 -C 4 )alkyl optionally substituted with one or more halogen atoms;

Y is O, S, or NR g ;

Cy 1 , Cy 2 , Cy 4 and Cy 6 are independently a C or N-attached known ring system selected from 3- to 8-membered carbocyclic or heterocyclic monocyclic ring, saturated or partially unsaturated; phenyl; 5- or 6-membered heteroaromatic ring; and 6- to 18-membered carbocyclic or heterocyclic polycyclic ring system, saturated, partially unsaturated, aromatic or partially aromatic;

Cy 3 , Cy 5 and Cy 7 are independently a C or N-attached known ring system selected from 3-to 8-membered carbocyclic or heterocyclic monocyclic ring, saturated or partially unsaturated; phenyl; and 5- or 6-membered heteroaromatic ring;

wherein in the carbocyclic rings all ring members are carbon atoms; and in the heterocyclic and heteroaromatic rings one or more ring members are selected from N, O and S; and

wherein in all saturated or partially unsaturated rings one or two members of the rings are optionally C(O) and/or C(NH) and/or C[N(C 1 -C 4 )alkyl].

2. The compound of formula (I) according to claim 1 , wherein in R 1 -R 3 , R f and each R g are independently selected from H and saturated or unsaturated (C 1 -C 6 )alkyl optionally substituted with one or more fluorine atoms.

3. The compound of formula (I) according to claim 1 , wherein R 1 -R 3 are independently selected from H, halogen, —NO 2 , —CN, R a , —OR a′ , —OC(O)R a′ , —OC(O)OR a′ , —OC(O)NR b R a′ , —NR b R a′ , —NR b C(O)R a′ , —NR b C(O)OR a′ , —NR b C(O)NR b R a′ , —NR b S(O) 2 R a′ , —SR a′ , —S(O)R a′ , —SO 2 R a′ , —SO 2 NR b R a′ , —C(O)R a′ , —C(O)OR a′ , —C(O)NR b R a′ , and —C(O)NR b OR a′ .

4. The compound of formula (I) according to claim 1 , wherein R 4 -R 7 are independently selected from halogen, —NO 2 , —CN, R c , —OR c , —NR d R c , —NR d C(O)R c , —NR d C(O)OR c , —NR d C(O)NR d R c , —NR d S(O) 2 R c , —S(O)R c , —SO 2 R c , —SO 2 NR d R c , —C(O)R c , —C(O)OR c , and —C(O)NR d R c .

5. The compound of formula (I) according to claim 1 , wherein R 2 and R 3 are independently selected from H, halogen, R a , —OR a′ , and —NR b R a′ ; and R 5 -R 7 are independently selected from H, halogen, R c , —OR c , and —NR d R c , wherein R a , R a′ , R b , R c and R d are independently selected from H and —(C 1 -C 4 )alkyl optionally substituted with one or more fluorine atoms.

6. A pharmaceutical or veterinary composition which comprises an effective amount of a compound of formula (I) as defined in claim 1 , or a pharmaceutically or veterinary acceptable salt thereof, or any stereoisomer either of the compound of formula (I) or of its pharmaceutically or veterinary acceptable salt, together with one or more pharmaceutically or veterinary acceptable excipients or carriers.

7. A method for antiftifibrinolytic and antihemorrhagic treatment comprising administering an effective amount of a compound of formula (I) as defined in claim 1 , or a pharmaceutically or veterinary acceptable salt thereof, or any stereoisomer either of the compound of formula (I) or of its pharmaceutically or veterinary acceptable salt, and one or more pharmaceutically or veterinary acceptable excipients or carriers, in a subject in need thereof.

8. A compound of formula (III)

wherein A, B, C, R 1 -R 7 are as defined in claim 1 , and R′ is H or a carboxy protective group selected from the group consisting of (C 1 -C 6 )alkyl, benzyl, p-methoxyphenyl, trimethylsilyl and [2-(Trimethylsilyl)ethoxy]methyl (SEM), with the proviso that compound (III) is other than 7-methoxycarbonyl-7-phenylsulphonyl-2-oxaspiro[2.4]heptane and (2S*,4R*)-2-Phenylsulfonyl-4-iodomethyl-6,11-dioxaspiro[4.6]undecane-2-carboxylic Acid Methyl Ester; or

a compound of formula (II)

wherein A, B, C, R 1 -R 7 are as defined in claim 1 , and R is an hydroxamic acid protective group selected from the group consisting of tetrahydro-2H-pyran-2-yloxy (THP), benzyl, 1-naphthylmethyl and dimethyloxybenzyl (DMB).